Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Mazorelvimab, an antibody targeting Rabies Virus Spike Glycoprotein G.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Manfidokimab, an antibody targeting IL-4Ralpha.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Litifilimab, an antibody targeting BDCA2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ligufalimab, an antibody targeting CD47.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Izalontamab, an antibody targeting EGFR × HER3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ifinatamab, an antibody targeting B7-H3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Gumokimab, an antibody targeting IL-17A.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Gefurulimab, an antibody targeting C5 × Albumin.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Danburstotug, an antibody targeting PD-L1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Crefmirlimab, an antibody targeting CD8A.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Anselamimab, an antibody targeting Light Chain Amyloid Fibrils.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Zigakibart, an antibody targeting APRIL.